Targeting virulence regulation to disarm Acinetobacter baumannii pathogenesis.

Autor: Trebosc V; BioVersys AG, Basel, Switzerland., Lucchini V; BioVersys AG, Basel, Switzerland.; Biozentrum, University of Basel, Basel, Switzerland., Narwal M; BioVersys SAS, Lille, France., Wicki B; BioVersys AG, Basel, Switzerland., Gartenmann S; BioVersys AG, Basel, Switzerland., Schellhorn B; BioVersys AG, Basel, Switzerland., Schill J; BioVersys AG, Basel, Switzerland., Bourotte M; BioVersys SAS, Lille, France., Frey D; Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institute, Villigen, Switzerland., Grünberg J; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland., Trauner A; BioVersys AG, Basel, Switzerland., Ferrari L; Microbiology Discovery, Aptuit Srl, an Evotec Company, Verona, Italy., Felici A; Microbiology Discovery, Aptuit Srl, an Evotec Company, Verona, Italy., Champion OL; Biosystems Technology Ltd, Exeter, UK., Gitzinger M; BioVersys AG, Basel, Switzerland., Lociuro S; BioVersys AG, Basel, Switzerland., Kammerer RA; BioVersys SAS, Lille, France., Kemmer C; BioVersys AG, Basel, Switzerland., Pieren M; BioVersys AG, Basel, Switzerland.

Publikováno v: Virulence [Virulence] 2022 Dec; Vol. 13 (1), pp. 1868-1883.

The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis.

Autor: Flipo M; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France., Frita R; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Bourotte M; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France.; BioVersys SAS, Lille, France., Martínez-Martínez MS; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Boesche M; Cellzome GmbH . A GSK Company, 69117 Heidelberg, Germany., Boyle GW; GSK, David Jack Centre for R&D, Park Road, Ware, Hertfordshire SG12 ODP, UK., Derimanov G; GSK, Clinical Pharmacology and Experimental Medicine, 1250 South Collegeville Road, Collegeville, PA 19426, USA., Drewes G; Cellzome GmbH . A GSK Company, 69117 Heidelberg, Germany., Gamallo P; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Ghidelli-Disse S; Cellzome GmbH . A GSK Company, 69117 Heidelberg, Germany., Gresham S; GSK, David Jack Centre for R&D, Park Road, Ware, Hertfordshire SG12 ODP, UK., Jiménez E; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., de Mercado J; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Pérez-Herrán E; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Porras-De Francisco E; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Rullas J; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Casado P; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Leroux F; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France.; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000 Lille, France., Piveteau C; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France., Kiass M; National Reference Center for Tuberculosis and Mycobacteria, Sciensano, Brussels, Belgium., Mathys V; National Reference Center for Tuberculosis and Mycobacteria, Sciensano, Brussels, Belgium., Soetaert K; National Reference Center for Tuberculosis and Mycobacteria, Sciensano, Brussels, Belgium., Megalizzi V; Microbiology, Bioorganic and Macromolecular Chemistry, Facult. de Pharmacie, Universit. Libre de Bruxelles, Brussels, Belgium., Tanina A; Microbiology, Bioorganic and Macromolecular Chemistry, Facult. de Pharmacie, Universit. Libre de Bruxelles, Brussels, Belgium., Wintjens R; Microbiology, Bioorganic and Macromolecular Chemistry, Facult. de Pharmacie, Universit. Libre de Bruxelles, Brussels, Belgium., Antoine R; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Brodin P; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France.; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000 Lille, France., Delorme V; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Moune M; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Djaout K; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Slupek S; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Kemmer C; BioVersys AG, Basel, Switzerland., Gitzinger M; BioVersys AG, Basel, Switzerland., Ballell L; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Mendoza-Losana A; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Lociuro S; BioVersys AG, Basel, Switzerland., Deprez B; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France.; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000 Lille, France., Barros-Aguirre D; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Remuiñán MJ; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Willand N; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France., Baulard AR; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France.; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000 Lille, France.

Publikováno v: Science translational medicine [Sci Transl Med] 2022 May 04; Vol. 14 (643), pp. eaaz6280. Date of Electronic Publication: 2022 May 04.

In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms.

Autor: Trebosc V; BioVersys AG, Basel, Switzerland., Schellhorn B; BioVersys AG, Basel, Switzerland., Schill J; BioVersys AG, Basel, Switzerland., Lucchini V; BioVersys AG, Basel, Switzerland.; Biozentrum, University of Basel, Basel, Switzerland., Bühler J; BioVersys AG, Basel, Switzerland., Bourotte M; BioVersys SAS, Lille, France., Butcher JJ; BioVersys AG, Basel, Switzerland., Gitzinger M; BioVersys AG, Basel, Switzerland., Lociuro S; BioVersys AG, Basel, Switzerland., Kemmer C; BioVersys AG, Basel, Switzerland., Dale GE; BioVersys AG, Basel, Switzerland.

Publikováno v: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2020 Dec 01; Vol. 75 (12), pp. 3552-3562.

A fragment-based approach towards the discovery of N-substituted tropinones as inhibitors of Mycobacterium tuberculosis transcriptional regulator EthR2.

Autor: Prevet H; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000, Lille, France., Moune M; Institut Pasteur de Lille, Univ. Lille, CNRS, Inserm, CHU Lille, U1019-UMR8204-CIIL-Centre d'Infection et d'Immunité de Lille, F-59000, Lille, France., Tanina A; Unité Microbiologie, Bioorganique et Macromoléculaire (CP206/04), département R3D, Faculté de Pharmacie, Université Libre de Bruxelles, B-1050, Brussels, Belgium., Kemmer C; Bioversys AG, Hochbergerstrasse 60C, 4057, Basel, Switzerland., Herledan A; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000, Lille, France., Frita R; Institut Pasteur de Lille, Univ. Lille, CNRS, Inserm, CHU Lille, U1019-UMR8204-CIIL-Centre d'Infection et d'Immunité de Lille, F-59000, Lille, France., Wohlkönig A; Structural Biology Brussels, Vlaams Instituut voor Biotechnology (VIB), B-1050, Brussels, Belgium., Bourotte M; Bioversys AG, Hochbergerstrasse 60C, 4057, Basel, Switzerland., Villemagne B; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000, Lille, France., Leroux F; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000, Lille, France., Gitzinger M; Bioversys AG, Hochbergerstrasse 60C, 4057, Basel, Switzerland., Baulard AR; Institut Pasteur de Lille, Univ. Lille, CNRS, Inserm, CHU Lille, U1019-UMR8204-CIIL-Centre d'Infection et d'Immunité de Lille, F-59000, Lille, France., Déprez B; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000, Lille, France., Wintjens R; Unité Microbiologie, Bioorganique et Macromoléculaire (CP206/04), département R3D, Faculté de Pharmacie, Université Libre de Bruxelles, B-1050, Brussels, Belgium., Willand N; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000, Lille, France. Electronic address: nicolas.willand@univ-lille.fr., Flipo M; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000, Lille, France.

Publikováno v: European journal of medicinal chemistry [Eur J Med Chem] 2019 Apr 01; Vol. 167, pp. 426-438. Date of Electronic Publication: 2019 Feb 10.

Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.

Autor: Boiteau JG; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France. Electronic address: jean-guy.boiteau@galderma.com., Ouvry G; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France. Electronic address: gilles.ouvry@galderma.com., Arlabosse JM; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Astri S; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Beillard A; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Bhurruth-Alcor Y; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Bonnary L; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Bouix-Peter C; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Bouquet K; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Bourotte M; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France., Cardinaud I; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Comino C; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Deprez B; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France., Duvert D; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Féret A; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Hacini-Rachinel F; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Harris CS; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Luzy AP; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Mathieu A; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France., Millois C; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Orsini N; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Pascau J; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Pinto A; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France., Piwnica D; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Polge G; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Reitz A; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Reversé K; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Rodeville N; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Rossio P; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Spiesse D; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Tabet S; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Taquet N; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Tomas L; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Vial E; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France., Hennequin LF; Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France.

Publikováno v: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2018 Feb 15; Vol. 26 (4), pp. 945-956. Date of Electronic Publication: 2017 Aug 02.